KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Amortizatization of Intangibles (2019 - 2025)

Arbutus Biopharma's Amortizatization of Intangibles history spans 7 years, with the latest figure at $541000.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 44.96% year-over-year to $541000.0; the TTM value through Sep 2025 reached $2.8 million, up 0.67%, while the annual FY2024 figure was $3.1 million, 42.76% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $541000.0 at Arbutus Biopharma, down from $668000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $983000.0 in Q3 2024 and bottomed at -$300000.0 in Q3 2021.
  • The 5-year median for Amortizatization of Intangibles is $534000.0 (2023), against an average of $332263.2.
  • The largest annual shift saw Amortizatization of Intangibles tumbled 8050.0% in 2021 before it skyrocketed 743.37% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$246000.0 in 2021, then skyrocketed by 191.06% to $224000.0 in 2022, then surged by 176.34% to $619000.0 in 2023, then soared by 49.11% to $923000.0 in 2024, then tumbled by 41.39% to $541000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Amortizatization of Intangibles are $541000.0 (Q3 2025), $668000.0 (Q2 2025), and $718000.0 (Q1 2025).